67
Participants
Start Date
October 16, 2020
Primary Completion Date
October 30, 2021
Study Completion Date
October 30, 2021
Favipiravir
Favipiravir is the experimental drug. The dosage for favipiravir to be used in this study for prophylaxis is 1600 mg (8 x 200 mg tablets) orally twice daily on day 1 followed by 800 mg (4 x 200 mg tablets) orally twice daily on days 2-25. The dose of favipiravir for treatment is 2000 mg orally twice daily on day 1, the 1000 mg orally twice daily for 13 additional days.
Favipiravir Placebo
Favipiravir Placebo is the placebo drug. For chemoprophylaxis, the dosage of favipiravir placebo is 8 tablets orally twice daily on day 1, followed by 4 tablets twice daily from days 2-25. The dosage of favipiravir placebo for treatment is 10 tablets orally twice daily on day 1, followed by tablets twice daily from days 2-14.
Mount Sinai Hospital, Toronto
Lead Sponsor
Collaborators (1)
MOUNT SINAI HOSPITAL
OTHER
Applied Health Research Centre
OTHER
Sunnybrook Health Sciences Centre
OTHER
University Health Network, Toronto
OTHER
University of Toronto
OTHER
Appili Therapeutics Inc.
INDUSTRY